165 related articles for article (PubMed ID: 37867623)
21. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P; Kawalec P; Pilc A
Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
[TBL] [Abstract][Full Text] [Related]
23. Treatment sequence network meta-analysis in Crohn's disease: a methodological case study.
Varu A; Wilson FR; Dyrda P; Hazel M; Hutton B; Cameron C
Curr Med Res Opin; 2019 May; 35(5):733-756. PubMed ID: 30727745
[TBL] [Abstract][Full Text] [Related]
24. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
[TBL] [Abstract][Full Text] [Related]
25. Ustekinumab is effective and safe in the treatment of Crohn's disease refractory to anti-TNFα in an orthotopic liver transplant patient.
Martínez-Montiel M; Piedracoba-Cadahia P; Gómez-Gómez C; Gonzalo J
J Crohns Colitis; 2015 Sep; 9(9):816-7. PubMed ID: 26071409
[No Abstract] [Full Text] [Related]
26. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
Singh S; Fumery M; Sandborn WJ; Murad MH
Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
[TBL] [Abstract][Full Text] [Related]
28. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease.
Scott FI; Hans AK; Gerich ME; Fennimore B; Mamtani R; Vajravelu RK; Lewis JD
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2082-2092.e10. PubMed ID: 32801006
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.
Cline A; Pichardo RO
Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738849
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
Sandborn WJ; Rutgeerts P; Gasink C; Jacobstein D; Zou B; Johanns J; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG
Aliment Pharmacol Ther; 2018 Jul; 48(1):65-77. PubMed ID: 29797519
[TBL] [Abstract][Full Text] [Related]
31.
Borrás-Blasco J; Cortes X; Fernandez-Martinez S; Casterá E; Antequera B
Am J Health Syst Pharm; 2017 Feb; 74(4):209-212. PubMed ID: 28179246
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
34. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE; Irving PM; Hoops T; Izanec JL; Gao LL; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB; Jairath V; Kuehbacher T; Lewis JD; Loftus EV; Mihaly E; Panaccione R; Scherl E; Shchukina OB; Sandborn WJ;
Lancet; 2022 Jun; 399(10342):2200-2211. PubMed ID: 35691323
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of biological therapy in pediatric patients with Crohn's disease.
Tarnok A; Kiss Z; Kadenczki O; Veres G
Expert Opin Biol Ther; 2019 Mar; 19(3):181-196. PubMed ID: 30601083
[TBL] [Abstract][Full Text] [Related]
36. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
[TBL] [Abstract][Full Text] [Related]
37. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
Aliment Pharmacol Ther; 2020 May; 51(10):948-957. PubMed ID: 32249966
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Deepak P; Loftus EV
Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
[TBL] [Abstract][Full Text] [Related]
39. Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P; Van Assche G; Vermeire S
Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
[TBL] [Abstract][Full Text] [Related]
40. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]